The focus of the Clinical Malaria Group is the evaluation of the safety and efficacy of candidate antimalarials, using the induced blood stage malaria (IBSM) model in healthy human volunteers.  Developed by the previous group lead Professor James McCarthy, the model has been used to evaluate 10 investigational medicinal products.  Models have been established for an artemisinin-sensitive and an artemisinin-resistant P. falciparum strain, and other Plasmodium species including P. vivax and P. malariae.  The model has also enabled the conduct of studies to evaluate transmission-blocking interventions, and has enabled the conduct of exploratory studies to evaluate immunological and pathophysiological response to infection.